Hojuhn is a biopharmaceutical leader and executive who has successfully led several R&D teams in start-up, and global large-pharmaceutical settings. His teams have progressed multiple novel agents through development in oncology, immune disorder, and neurodegeneration. Before founding Pinetree Therapeutics, Ho-Juhn was Head of R&D at Genosco, Inc and invented and developed several clinical assets. One of the most successful pipelines was the Lazertinib, the 3rd generation EGFR inhibitor and licensed to Jassen in value of $1.25 billion. Prior to that, he was a project team leader for novel target discovery in Functional Genomics and Developmental Molecular Pathway at Novartis Institute for Biomedical Research and successfully generated multiple clinical candidates in multiple therapeutic areas. Ho-Juhn earned a Ph.D. in Genetics and Neurobiology at Oregon State University and completed a post-doctoral fellowship at Novartis AG. He received M.S in Genetics and a B.Sc. In Biology from Chungnam National University, S. Korea.